Loading candles…
Morepen Laboratories Ltd is an Indian pharmaceutical company engaged in manufacturing, producing, developing, and marketing a broad range of pharmaceutical products. The company operates through several specialized business units and holds a significant position in the global active pharmaceutical ingredients (API) market. Its business segments include APIs, branded and generic formulations, home health products, medical devices (home diagnostics), and finished dosages. Morepen produces APIs including molecules such as Loratadine, Montelukast, and Atorvastatin. The company maintains manufacturing facilities that comply with international regulatory standards, including those of the USFDA. Though headquartered in India, its operations serve the global market. Morepen operates within the pharmaceuticals and medical devices industries.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | MOREPENLAB : 26-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 22, 2026 has been re-scheduled. Further, the Company… | 26 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and other business matters | 10 Feb 2026 |
| Unaudited Results - Q2 & FY25 | To consider and approve un-audited standalone and consolidated financial results of the company for the quarter and half year ended 30th September 2025 | 14 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 6 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters | 12 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.